Oxidative stress and atherosclerosis in early chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2686-2690

  Zalba, Guillermo ^a,b   Fortuño, Ana ^a,b   Díez, Javier ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Atherosclerosis; Chronic renal disease; Oxidative stress

Indexed keywords

ANTIOXIDANT; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; KIDNEY FAILURE; LEUKOCYTE; MACROPHAGE; MORBIDITY; MORTALITY; NONHUMAN; NOTE; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEADY STATE; STROKE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS;

EID: 33749623475     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl398     Document Type: Note

References (32)

1. Babior BM. NADPH oxidase: An update. Blood 1999; 93: 1464-1476
2. Johnson F, Giulivi C. Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005; 26: 340-352
3. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-571
4. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: Enzymology and physiological implications. Free Radic Res 2003; 37: 121-127
5. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 5: C1424-C1437
6. Stocker R, Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478
7. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501
8. Kalinina N, Agrotis A, Tararak E et al. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2002; 22: 2037-2043
9. Sorescu D, Weiss D, Lassegue B et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-1435
10. Azumi H, Inoue N, Ohashi Y et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris. Important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2002; 22: 1838-1844
11. Faraci FM, Didion SP. Vascular protection. Superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004; 24: 1367-1373
12. Fukai T, Folz RJ, Landmesser U et al. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res 2002; 55: 239-249
13. Landmesser U, Merten R, Spiekermann S et al. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000; 101: 2264-2270
14. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065
15. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
16. Redón J, Cea-Calvo L, Lozano JV et al. Kidney function and cardiovascular disease in the hypertensive population: The ERIC-HTA study. J Hypertens 2006; 24: 663-669
17. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351: 1344-1346
18. Locatelli F, Canaud B, Eckardt K-U et al. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280
19. Vaziri ND. Oxidative stress in uremia: Nature, mechanisms, and potential consequences. Semin Nephrol 2004; 24: 469-473
20. Fortuño A, Beloqui O, San José G et al. Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. Kidney Int 2005; 68 [Suppl 99]: S71-S75
21. Galli F, Varga Z, Balla J et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int 2001; 59 [Suppl 78]: S148-S154
22. Sardenberg C, Suassuna P, Watanabe R et al. Balance between cytokine production by peripheral blood mononuclear cells and reactive oxygen species production by monocytes in patients with chronic kidney disease. Ren Fail 2004; 26: 673-681
23. Fortuño A, San José G, Moreno MU et al. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006; 55: 209-215
24. Witko-Sarsat V, Gausson V, Nguyen A-T et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82-91
25. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
26. Zalba G, Beloqui O, San José G et al. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005; 25: 1452-1457
27. Mancini GBJ, Dahlöf B, Díez J. Surrogate markers for cardiovascular diseases: Structural markers. Circulation 2004; 109 [Suppl IV]: IV-22-IV-30
28. Yilmaz MI, Saglam M, Caglar K et al. The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50
29. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease. Lancet 2001; 358: 2113-2117
30. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2031-2037
31. Violi F, Cangemi R. Antioxidants and cardiovascular disease. Curr Opin Investig Drugs 2005; 6: 890-895
32. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006; 11: 524-533